Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early antibody treatment, inflammation, and risk of post-COVID conditions
Kelly A. Gebo, Sonya L. Heath, Yuriko Fukuta, et al.
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 15

Showing 15 citing articles:

Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition
Noemí Cárdenas‐Rodríguez, Iván Ignacio‐Mejía, José Correa‐Basurto, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3805-3805
Open Access | Times Cited: 4
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 2
Unveiling the occurrence of COVID-19 in a diverse Bangladeshi population during the pandemic
Mahmud Hossain, Rezowana Mannan, Sohidul Islam, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 2
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
Feben Habtehyimer, Xianming Zhu, Andrew D. Redd, et al.
Microbiology Spectrum (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 5
Post-Acute Sequelae of COVID (PASC or Long COVID): An Evidenced-based Approach
Daniel O. Griffin
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 9
Open Access | Times Cited: 1
Hyperimmune Plasma and Immunoglobulins Against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
(2023)
Open Access | Times Cited: 3
Intravenous immunoglobulin as a potential treatment for long COVID
Matthew W. McCarthy
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1211-1217
Closed Access | Times Cited: 3
Is convalescent plasma still useful as a covid treatment?
Katharine Lang
BMJ (2023), pp. p2185-p2185
Open Access | Times Cited: 2
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial
Teresa H. Evering, Carlee Moser, Nikolaus Jilg, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102787-102787
Open Access
Distinct proteomic signatures in Ethiopians predict acute and long-term sequelae of COVID-19
Dawit Wolday, Abrha Gebreselema Gebrehiwot, Muhammed Ahmed Rameto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival
John I. Robinson, Laura R. Marks, Andrew L. Hinton, et al.
mBio (2024)
Closed Access
Long COVID across SARS‐CoV‐2 variants: Clinical features, pathogenesis, and future directions
Laurence S. C. Lok, Shuvam Sarkar, Chi‐Ming Lam, et al.
MedComm – Future Medicine (2024) Vol. 3, Iss. 4
Closed Access
Hydrogen Sulfide Ameliorates SARS-CoV-2-Associated Lung Endothelial Barrier Disruption
Olivier Escaffre, Peter Szaniszlo, Gábor Törő, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1790-1790
Open Access | Times Cited: 1
Igniting the slow burn of post-COVID conditions
Jeffrey P. Henderson
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 1
COVID-19 Convalescent Plasma Therapy: Long-term Implications
Hyunah Yoon, Yi Li, Keith Goldfeld, et al.
Open Forum Infectious Diseases (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Page 1

Scroll to top